NTT Communications: Digital Event Connects Tokyo and Kanazawa via World's Longest IOWN APN to Commemorate Hokuriku Shinkansen Line's Extension
NTT Communications Corporation (NTT Com) and the Hokuriku Regional Office of NTT DOCOMO, INC. (DOCOMO), together with the city of Kanazawa, celebrated the opening of a new section of the Hokuriku Shinkansen Line between Kanazawa and Tsuruga by holding digital events on March 16 under the theme of "Connection," a key component of NTT Group’s Innovative Optical and Wireless Network (IOWN) concept.1
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240325762257/en/
Scheme of live remote performance (Graphic: Business Wire)
The events included a live remote performance that seamlessly connected musicians in Kanazawa and Tokyo, a distance of about 1,000 kilometers, via the All-Photonics Network (APN). For the connection, NTT Com provided its APN Leased Line Plan powered by IOWN,2 which used the longest optical cable ever deployed in an IOWN demonstration and the first to be deployed in Japan's Hokuriku region.
The event brought together the Kanazawa Junior Jazz Orchestra JAZZ-21, consisting mainly of middle and high school students who have performed at the areas affected by the Great East Japan Earthquake and various major festivals around the world, and celebrated violinist Mayu Kijima, winner of numerous international competitions, including the 1st Shanghai Isaac Stern International Violin Competition in 2016, who performed with the Walner violin made by Antonio Stradivari 1699, which was on loan from the Munetsugu Collection.
Kanazawa City provided the demonstration environment and operated the venue in its area and NTT Com provided the APN transmission equipment and the venue in Tokyo. NTT Com and DOCOMO livestreamed the event on Kanazawa's metaverse platform using DOCOMO's 5G video transmission system, allowing viewers at home to enjoy the live event on PCs, smartphones and tablets via the browser-based virtual space platform DOOR.3 In addition, DOCOMO used its Hide Mode4 function to allow more people than normal to enter the virtual room. This was the first time in Japan that a metaverse space open to the public was used for a music event.
In another demonstration, smart lighting was used to allow spectators to digitally interact with Kanazawa's famous Tsuzumi-mon Gate to influence its illumination on the evening of March 16. Using 5G communication and IoT technology, spectators were able change the illumination by selecting from eight patterns via tablets placed near the gate. The demonstration, called “Connecting with Tsuzumi-mon Gate,” allowed people to make a special connection with the iconic site, including to take commemorative photos.
A third commemorative demonstration on March 16, called “Connecting with Other Locations,” allowed visitors to the Underground Plaza of the Motenashi Dome near Kanazawa Station to view and experience famous scenes along the Hokuriku Shinkansen line via a wide-angle virtual reality display without the use of goggles. During the demonstration, multiple people simultaneously enjoyed videos, 360-degree images and metaverse spaces, and even the experience of sitting in a Shinkansen driver's seat while traveling on the newly extended Hokuriku Shinkansen line.
DOCOMO group, under an agreement signed with the city of Kanazawa and West Japan Railway Company in 2019, is working to promote local attractions using 5G and other advanced technologies. Following the recent Noto Peninsula Earthquake on January 1, DOCOMO has strengthened its efforts to work with the people of the Hokuriku region to revitalize the region and support its recovery and reconstruction. Going forward, based on the lessons learned from the event to commemorate the Hokuriku Shinkansen Line's extension, NTT Com and DOCOMO are committed to providing new value to Kanazawa citizens and customers by incorporating new technologies, including the IOWN APN where possible, to promote the attractiveness of Kanazawa and contribute to the revitalization of the region.
1 Network infrastructure concept for creating an enriched society using advanced optical technologies, etc. IOWN® is a trademark of NTT Corporation. https://www.rd.ntt/e/iown/
2 NTT Com began offering APN communication services spanning prefectures from March 1 to meet customers' needs for advanced communication infrastructure.
3 DOCOMO's subsidiary NTT QONOQ INC. (https://www.nttqonoq.com/?lang=en) provides this service for holding events and displaying content in virtual spaces.
4 While 24 people is the normal recommended capacity of a virtual room, Hide Mode is a paid option that allows hundreds of people to enter, with certain limited capabilities. Please visit https://door.ntt/web/faq/index.html.
About NTT Communications
NTT Communications solves global technology challenges by helping enterprises utilize managed IT-infrastructure solutions to overcome complexity and risk in their IT environments. These solutions are backed by our worldwide infrastructure, including industry-leading, global tier-1 public and private networks reaching over 190 countries/regions, the world's most advanced data-center facilities (more than 500,000m2) and cutting-edge technologies for cloud, security and AI. As the core provider of the DOCOMO group's enterprise-business services and solutions, we create value by providing global-scale support for restructuring in industry and society, new workstyles and digital transformation in communities, leveraging 5G, IoT and other technologies under the "docomo business" brand. Together with NTT Ltd., NTT Data and NTT DOCOMO, we are the NTT Group.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com
About NTT DOCOMO
NTT DOCOMO, Japan’s leading mobile operator with over 89 million subscriptions, is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240325762257/en/
Contact information
For more information
Public Relations Office
NTT Communications Corporation
Phone: +81(0)3-6700-4010
Email: pr-cp@ntt.com
Hokuriku Regional Office
NTT DOCOMO, INC.
Phone: +81(0)76-225-2080
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
